newsfilter
← Latest News
GlobeNewswire·

ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant